Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid–Mediated Pretargeting: In Vivo Proof of Principle

Kristina Westerlund; Mohamed Altai; Bogdan Mitran; Mark Konijnenberg; Maryam Oroujeni; Christina Atterby; Marion de Jong; Anna Orlova; Johanna Mattsson; Patrick Micke; Amelie Eriksson Karlström; Vladimir Tolmachev

doi:10.2967/jnumed.118.208348

Research ArticleTheranostics

Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid–Mediated Pretargeting: In Vivo Proof of Principle

Kristina Westerlund, Mohamed Altai, Bogdan Mitran, Mark Konijnenberg, Maryam Oroujeni, Christina Atterby, Marion de Jong, Anna Orlova, Johanna Mattsson, Patrick Micke, Amelie Eriksson Karlström and Vladimir Tolmachev

Journal of Nuclear Medicine July 2018, 59 (7) 1092-1098; DOI: https://doi.org/10.2967/jnumed.118.208348

Kristina Westerlund

1Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mohamed Altai

2Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Bogdan Mitran

3Division of Molecular Imaging, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mark Konijnenberg

4Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Maryam Oroujeni

2Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christina Atterby

2Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Marion de Jong

4Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Anna Orlova

3Division of Molecular Imaging, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Johanna Mattsson

2Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Patrick Micke

2Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Amelie Eriksson Karlström

1Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Vladimir Tolmachev

2Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 59, Issue 7

July 1, 2018

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid–Mediated Pretargeting: In Vivo Proof of Principle

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid–Mediated Pretargeting: In Vivo Proof of Principle

Journal of Nuclear Medicine Jul 2018, 59 (7) 1092-1098; DOI: 10.2967/jnumed.118.208348

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid–Mediated Pretargeting: In Vivo Proof of Principle

Journal of Nuclear Medicine Jul 2018, 59 (7) 1092-1098; DOI: 10.2967/jnumed.118.208348

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This Month in JNM

PubMed
Google Scholar

Cited By...

Designed Ankyrin Repeat Protein-Mediated Peptide Nucleic Acid-Based Pretargeting: A Proof-of-Principle Study
Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting
Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein {alpha}
Efficacy of HER2-Targeted Intraperitoneal 225Ac {alpha}-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis
Pretargeting: A Path Forward for Radioimmunotherapy
Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts

Google Scholar

Theranostics

Determination of the Intralesional Distribution of Theranostic ¹²⁴I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
Evidence-Based Clinical Protocols to Monitor Efficacy of [¹⁷⁷Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
¹⁷⁷Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer

Show more Theranostics

Basic

Dopamine D₁ Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
Optical Navigation of the Drop-In γ-Probe as a Means to Strengthen the Connection Between Robot-Assisted and Radioguided Surgery
Synthesis and Preclinical Evaluation of a ⁶⁸Ga-Labeled Adnectin, ⁶⁸Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression

Show more Basic

Keywords

pretargeting
PNA
affibody molecules
radionuclide therapy
HER2

Main menu

User menu

Search

Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid–Mediated Pretargeting: In Vivo Proof of Principle

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Theranostics

Basic

Similar Articles

Keywords